Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 204-206, 2017.
Artigo em Chinês | WPRIM | ID: wpr-511755

RESUMO

Objective To study the effect of Trimebutine maleate tablets on serum tumor necrosis factor(TNF)-α,interleukin(IL)-23,erythrocyte sedimentation rate(ESR),D-dimer(D-D)ulcerative colitis in patients with ulcerative colitis.Methods 92 patients of ulcerative colitis who received therapy from October 2014 to October 2016 in our hospital were selected.According to random number table,those patients were divided into the observation group(n=46)and the control group(n=46).The control group was treated with mesalazine slow release tablets,while the observation group was treated with trimebutine maleate tablets on this basis.After 8 weeks of treatment,the changes of the disease activity index(Sutherland DAI score),TNF-α,IL-23,ESR,D-D and clinical effect were compared.Results After treatment,the Sutherland DAI score in the observation group was significantly lower than that of the control group DAI(P<0.05); the TNF-αand IL-23 in the observation group were significantly lower than that of the control group(all P<0.05); the ESR and D-D in the observation group were significantly lower than that of the control group(all P<0.05); the total effective rate in the observation group was significantly higher than that of the control group[93.48%(43/46)vs.69.57%(32/46)](P<0.05).Conclusion Trimebutine maleate tablets is well for ulcerative colitis,which can effectively reduce inflammation,improve hypercoagulable state,promote the recovery of the disease,it is worthy of application and promotion.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA